|
NEW YORK(BUSINESS WIRE)
ZIOPHARM Oncology, Inc. (Nasdaq: ZIOP) announced today that the Company
will host an analyst and institutional investor meeting on Thursday,
November 19, 2009 from 7:30 A.M. to 9:30 A.M. Eastern Time in New York
City.
The event will be moderated by Jonathan Lewis, MD, PhD, Chief Executive
Officer of ZIOPHARM and will be comprised of an in-depth panel
discussion of the Company's product pipeline and clinical and regulatory
development strategy. The presentation will include presentations by
several well known global experts as well as ZIOPHARM's management and
will include a question and answer session with the panel.
The meeting will be webcast live and may be accessed by visiting the
Investor Relations section at www.ziopharm.com.
The webcast will be archived for ninety days.
About ZIOPHARM Oncology, Inc.:
ZIOPHARM Oncology is a biopharmaceutical company engaged in the
development and commercialization of a diverse portfolio of cancer
drugs. The Company is currently focused on three clinical programs.
Palifosfamide (ZymafosTM or ZIO-201) references a novel
composition (tris formulation) that is the functional active metabolite
of ifosfamide, a standard of care for treating sarcoma, lymphoma,
testicular, and other cancers.Palifosfamide delivers only the cancer
fighting component of ifosfamide. It is expected to overcome the
resistance seen with ifosfamide and cyclophosphamide, two of the most
commonly used alkylating drugs used to treat certain cancers.
Palifosfamide does not have the toxic metabolites of ifosfamide that
cause the debilitating side effects of fuzzy brain? (encephalopathy)
and severe bladder inflammation. Intravenous palifosfamide is currently
in a randomized Phase II trial to treat unresectable or metastatic soft
tissue sarcoma in the front- and second-line setting, a study expected
to establish the basis for a registration trial as early as the first
half of 2010.An oral form of palifosfamide has been developed
preclinically to the investigational new drug application stage.
Darinaparsin (ZinaparTM or ZIO-101) is a novel organic
arsenic being developed for the treatment of various hematologic and
solid cancers. Preclinical and clinical studies to date have
demonstrated that darinaparsin is considerably less toxic than inorganic
arsenic, particularly with regard to cardiac toxicity. Phase I and Phase
II testing of the intravenous form of darinaparsin in solid tumors and
hematological cancers has been completed or is nearing completion. The
Company has reported clinical activity and, importantly, a safety
profile from these studies as predicted by preclinical results.
Favorable results from the trial with IV-administered darinaparsin in
lymphoma, particularly peripheral T-cell lymphoma (PTCL?), were
reported at the American Society of Clinical Oncology (ASCO) in May.
Supported by these data, the Company expects to advance into a
registration trial in peripheral T-cell lymphoma as early as the first
half of 2010. Also as reported at ASCO, in ongoing Phase I trials the
oral form is active and well tolerated.
Indibulin (ZybulinTM or ZIO-301) is a novel, oral
tubulin binding agent that targets both mitosis and cancer cell
migration. Indibulin is expected to have several potential benefits,
including oral dosing, application in multi-drug resistant tumors, no
neuropathy and minimal overall toxicity. In multiple Phase I
trials in cancer patients, oral indibulin has been administered both as
a single agent and in combination with favorable activity and a
promising safety profile that does not include the neurotoxicity seen
with all of the other classes of tubulin binding agents. Most recently,
results of oral indibulin in combination with oral capecitabine (Xeloda)
were presented at this year's American Society of Clinical Oncology
(ASCO) along with the preclinical findings of a novel dosing schedule
conducted under the direction of Dr. Larry Norton. The Company expects
to initiate a Phase I/II study of oral indibulin in breast cancer
patients employing this dosing schedule established preclinically. Once
the maximum tolerated dose is established in the Phase I portion of the
trial, Phase II will proceed with an expanded population.
ZIOPHARM's operations are located in Boston, MA with an executive office
in New York City.Further information about ZIOPHARM may be found at www.ziopharm.com.
ZIOP-G
Forward-Looking Safe Harbor Statement:
This press release contains forward-looking statements for ZIOPHARM
Oncology, Inc. that involve risks and uncertainties that could cause the
Company's actual results to differ materially from the anticipated
results and expectations expressed in these forward-looking statements.
These statements are based on current expectations, forecasts and
assumptions that are subject to risks and uncertainties, which could
cause actual outcomes and results to differ materially from these
statements. Among other things, there can be no assurance that any of
the Company's development efforts relating to its product candidates
will be successful, or such product candidates will be successfully
commercialized. Other risks that affect forward-looking information
contained in this press release include the possibility of being unable
to obtain regulatory approval of the Company's product candidates, the
risk that final trial data may not support interim analysis and that the
results of clinical trials in general may not support the Company's
claims, risks related to the Company's ability to protect its
intellectual property, risks related to its reliance on third parties to
develop its product candidates, risks related to the sufficiency of
existing capital reserves to fund continued operations for a particular
amount of time and uncertainties regarding the Company's ability to
obtain additional financing to support its operations thereafter. The
Company assumes no obligation to update these forward-looking
statements, except as required by law.
S.A. Noonan Communications, LLC
Susan Noonan, 212-966-3650
susan@sanoonan.com
or
Media
Rx
Communications Group
Eric Goldman, 917-322-2563
egoldman@rxir.com
Source: ZIOPHARM Oncology, Inc.
|
